Spray-Dried Sealant Helps Control Surgical Bleeding
By HospiMedica International staff writers Posted on 13 May 2015 |
Image: Raplixa application for forming a blood clot (Photo courtesy of The Medicines Company).
A novel spray-dried human fibrin sealant helps control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature, or cautery are ineffective or impractical.
Raplixa contains powdered fibrinogen and thrombin that are purified, spray-dried, blended, and packaged in a vial, using a manufacturing process that includes virus inactivation and other steps that help reduce the risk of transmission of blood-borne viruses. Each gram of Raplixa contains 79 mg human fibrinogen and 726 IU human thrombin, and the powder is available in three different presentations: 0.5, 1.0, and 2.0 grams.
Raplixa requires no thawing, reconstitution, or mixing, and can be applied either directly from the vial or with the RaplixaSpray device, a low-pressure spray applicator designed to reach larger bleeding surfaces and difficult to reach areas by using medical CO2 gas or medical grade air as the propellant. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. Conversion of fibrinogen into fibrin occurs by the splitting of fibrinogen into fibrin monomers and fibrinopeptides.
The fibrin monomers then aggregate and form a fibrin clot. Factor XIIIa, which is activated from factor XIII by thrombin, then cross-links the fibrin. As wound healing progresses, increased fibrinolytic activity is induced by plasmin, causing the fibrin to degrade. Raplixa is a product of The Medicines Company (Parsippany, NJ, USA), and has been approved for use by the US Food and Drug Administration (FDA) for use in conjunction with an absorbable gelatin sponge.
“Controlling mild to moderate bleeding during surgery requires a hemostatic agent that is easy-to-use and works well across a range of bleeding settings,” said Grant Bochicchio, MD, MPH, of Washington University School of Medicine (St. Louis, MO, USA). “RAPLIXA and the RaplixaSpray device provide surgeons with a potential off-the-shelf solution ready to address the challenging bleeding situations we encounter every day.”
Related Links:
The Medicines Company
Raplixa contains powdered fibrinogen and thrombin that are purified, spray-dried, blended, and packaged in a vial, using a manufacturing process that includes virus inactivation and other steps that help reduce the risk of transmission of blood-borne viruses. Each gram of Raplixa contains 79 mg human fibrinogen and 726 IU human thrombin, and the powder is available in three different presentations: 0.5, 1.0, and 2.0 grams.
Raplixa requires no thawing, reconstitution, or mixing, and can be applied either directly from the vial or with the RaplixaSpray device, a low-pressure spray applicator designed to reach larger bleeding surfaces and difficult to reach areas by using medical CO2 gas or medical grade air as the propellant. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. Conversion of fibrinogen into fibrin occurs by the splitting of fibrinogen into fibrin monomers and fibrinopeptides.
The fibrin monomers then aggregate and form a fibrin clot. Factor XIIIa, which is activated from factor XIII by thrombin, then cross-links the fibrin. As wound healing progresses, increased fibrinolytic activity is induced by plasmin, causing the fibrin to degrade. Raplixa is a product of The Medicines Company (Parsippany, NJ, USA), and has been approved for use by the US Food and Drug Administration (FDA) for use in conjunction with an absorbable gelatin sponge.
“Controlling mild to moderate bleeding during surgery requires a hemostatic agent that is easy-to-use and works well across a range of bleeding settings,” said Grant Bochicchio, MD, MPH, of Washington University School of Medicine (St. Louis, MO, USA). “RAPLIXA and the RaplixaSpray device provide surgeons with a potential off-the-shelf solution ready to address the challenging bleeding situations we encounter every day.”
Related Links:
The Medicines Company
Latest Surgical Techniques News
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery
- Robotic Nerve ‘Cuffs’ Could Treat Various Neurological Conditions
- Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons
- Next-Gen Computer Assisted Vacuum Thrombectomy Technology Rapidly Removes Blood Clots